Breakthrough Drug for Type 1 Diabetes Approved in the UK

The Next Steps for UK Patients
While the MHRA's licensing of teplizumab is a major victory, the drug is not yet routinely available on the National Health Service (NHS). The next critical step is for the National Institute for Health and Care Excellence (NICE) to review the drug's clinical and cost-effectiveness and determine whether it should be made available to eligible patients through the NHS. A draft guidance on this is expected, and the decision will be pivotal in ensuring that this breakthrough treatment can reach everyone in the UK who could benefit from it. Patient advocacy groups like Diabetes UK are actively campaigning to ensure teplizumab is made available on the NHS and that a screening program is rolled out to identify those in the early stages of the condition.